Table 5.
Discontinuation/dose reduction or AE due to targeted therapy.
| Total Cohort n = 242 |
CTRL n = 160 |
COMB n = 82 |
Significance p-Value |
|
|---|---|---|---|---|
| AE due to targeted treatment, n (%) | 5 (2.1) | 5 (3.1) | 0 | 0.254 |
| Disruption of targeted treatment, n (%) | 6 (2.9) | 5 (3.1) | 1 (1.2) | 0.642 |
| Dose reduction of targeted treatment, n (%) | 8 (3.3) | 5 (3.1) | 3 (3.7) | 1.0 |
| Any event (AE or therapy adjustment §), n (%) | 14 (5.8) | 10 (6.3) | 3 (4.9) | 0.586 |
Information on the continuation of targeted therapy; §) comparison of COMB group vs. CTRL group: (χ2 = 0.020, p = 0.88).